ImClone Hammered as Sales Lag Estimates

ImClone Hammered as Sales Lag Estimates Scandal-plagued ImClone Systems may have fallen off the road to recovery. While the company’s second-quarter earnings beat Wall Street estimates, the stock plunged yesterday on disappointing sales of the company’s key cancer drug.


Wanted: Drugs to Fight Bioterror

Wanted: Drugs to Fight Bioterror “Amid new warnings about a possible summer of terror, the U.S. government is preparing to spend billons to coax pharmaceutical companies to develop drugs to fend off a biological or chemical attack. But experts say the infusion of cash may be little more than a good start.”


The Drug Research War

The Drug Research War “Mention the term ‘outsourcing,’ and drug development probably doesn’t leap to mind. But this market, which is the heart of pharmaceutical and biotech companies, is growing at a yearly clip of 15% to 20%. Right now the lion’s share of the work has gone to U.S. companies that focus on drug […]


Will U.S. try to circumvent drug firms patent?

Will U.S. try to circumvent drug firms patent? : The furor over Abbott Laboratories’ 400 percent price increase last December of the AIDS drug Norvir has resulted in an unprecedented meeting at the National Institutes of Health to consider circumventing the drug giant’s patent.


Do NOT follow this link or you will be banned from the site!
%d bloggers like this: